CTIC Stock - Cell Therapeutics Inc.

CTIC Stock Chart

CTIC Profile

CTI BioPharma Corp., a Seattle-based biopharmaceutical firm, specializes in acquiring, developing, and commercializing innovative targeted therapies designed to combat blood-related cancers across the United States. The company's flagship product, VONJO (pacritinib), stands as an investigational oral kinase inhibitor uniquely targeting JAK2, FLT3, IRAK1, and CSF1R, primarily intended for adult patients grappling with myelofibrosis.

In pursuit of its therapeutic goals, CTI BioPharma has forged strategic license and collaboration agreements with industry leaders such as Teva Pharmaceutical Industries Ltd., S*BIO Pte Ltd., and Baxalta, bolstering its capabilities and expanding its reach within the biopharmaceutical sector.

Founded in 1991 under the name Cell Therapeutics, Inc., the company rebranded to CTI BioPharma Corp. in May 2014, marking a strategic evolution in its corporate identity and mission. Headquartered in the biotech hub of Seattle, Washington, CTI BioPharma continues to leverage its deep-rooted expertise and collaborative partnerships to advance the development and commercialization of cutting-edge therapies aimed at addressing critical unmet medical needs in hematology and oncology.

With a commitment to pioneering advancements in cancer treatment, CTI BioPharma remains steadfast in its dedication to delivering novel therapies that improve patient outcomes and quality of life, underscoring its pivotal role in the biopharmaceutical landscape.

CTIC Revenue Chart

CTIC Earnings

Analyst Ratings